Bullock M - Search Results

1

ETS Factor ETV5 Activates the Mutant Telomerase Reverse Transcriptase Promoter in Thyroid Cancer.

Bullock M, Lim G, Zhu Y, Åberg H, Kurdyukov S, Clifton-Bligh R. Bullock M, et al. Thyroid. 2019 Nov;29(11):1623-1633. doi: 10.1089/thy.2018.0314. Epub 2019 Oct 29. Thyroid. 2019. PMID: 31452441

2

Contribution of a common variant in the promoter of the 1-α-hydroxylase gene (CYP27B1) to fracture risk in the elderly.

Clifton-Bligh RJ, Nguyen TV, Au A, Bullock M, Cameron I, Cumming R, Chen JS, March LM, Seibel MJ, Sambrook PN. Clifton-Bligh RJ, et al. Among authors: bullock m. Calcif Tissue Int. 2011 Feb;88(2):109-16. doi: 10.1007/s00223-010-9434-4. Epub 2010 Nov 25. Calcif Tissue Int. 2011. PMID: 21107545 Free PMC article.

3

BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer.

O'Neill CJ, Bullock M, Chou A, Sidhu SB, Delbridge LW, Robinson BG, Gill AJ, Learoyd DL, Clifton-Bligh R, Sywak MS. O'Neill CJ, et al. Among authors: bullock m. Surgery. 2010 Dec;148(6):1139-45; discussion 1145-6. doi: 10.1016/j.surg.2010.09.005. Surgery. 2010. PMID: 21134544

4

Multikinase inhibitors: a new option for the treatment of thyroid cancer.

Gild ML, Bullock M, Robinson BG, Clifton-Bligh R. Gild ML, et al. Among authors: bullock m. Nat Rev Endocrinol. 2011 Aug 23;7(10):617-24. doi: 10.1038/nrendo.2011.141. Nat Rev Endocrinol. 2011. PMID: 21862995 Review.

5

Association of FOXE1 polyalanine repeat region with papillary thyroid cancer.

Bullock M, Duncan EL, O'Neill C, Tacon L, Sywak M, Sidhu S, Delbridge L, Learoyd D, Robinson BG, Ludgate M, Clifton-Bligh RJ. Bullock M, et al. J Clin Endocrinol Metab. 2012 Sep;97(9):E1814-9. doi: 10.1210/jc.2012-1456. Epub 2012 Jun 26. J Clin Endocrinol Metab. 2012. PMID: 22736773

6

Somatic Mutations of FOXE1 in Papillary Thyroid Cancer.

Mond M, Bullock M, Yao Y, Clifton-Bligh RJ, Gilfillan C, Fuller PJ. Mond M, et al. Among authors: bullock m. Thyroid. 2015 Aug;25(8):904-10. doi: 10.1089/thy.2015.0030. Epub 2015 Jun 19. Thyroid. 2015. PMID: 25950909

7

TERT promoter mutations are a major indicator of recurrence and death due to papillary thyroid carcinomas.

Bullock M, Ren Y, O'Neill C, Gill A, Aniss A, Sywak M, Sidhu S, Delbridge L, Learoyd D, de Vathaire F, Robinson BG, Clifton-Bligh RJ. Bullock M, et al. Clin Endocrinol (Oxf). 2016 Aug;85(2):283-90. doi: 10.1111/cen.12999. Epub 2016 Feb 8. Clin Endocrinol (Oxf). 2016. PMID: 26667986 Free PMC article.

8

DNA Methylation Analysis: Choosing the Right Method.

Kurdyukov S, Bullock M. Kurdyukov S, et al. Among authors: bullock m. Biology (Basel). 2016 Jan 6;5(1):3. doi: 10.3390/biology5010003. Biology (Basel). 2016. PMID: 26751487 Free PMC article. Review.

9

NRASQ61R Mutation-specific Immunohistochemistry Also Identifies the HRASQ61R Mutation in Medullary Thyroid Cancer and May Have a Role in Triaging Genetic Testing for MEN2.

Reagh J, Bullock M, Andrici J, Turchini J, Sioson L, Clarkson A, Watson N, Sheen A, Lim G, Delbridge L, Sidhu S, Sywak M, Aniss A, Shepherd P, Ng D, Oei P, Field M, Learoyd D, Robinson BG, Clifton-Bligh RJ, Gill AJ. Reagh J, et al. Among authors: bullock m. Am J Surg Pathol. 2017 Jan;41(1):75-81. doi: 10.1097/PAS.0000000000000740. Am J Surg Pathol. 2017. PMID: 27635947

10

Thyroid transcription factor FOXE1 interacts with ETS factor ELK1 to co-regulate TERT.

Bullock M, Lim G, Li C, Choi IH, Kochhar S, Liddle C, Zhang L, Clifton-Bligh RJ. Bullock M, et al. Oncotarget. 2016 Dec 27;7(52):85948-85962. doi: 10.18632/oncotarget.13288. Oncotarget. 2016. PMID: 27852061 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

518 results

Search Page